| 6.08 0.02 (0.33%) | 12-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.3 | 1-year : | 8.53 |
| Resists | First : | 6.25 | Second : | 7.3 |
| Pivot price | 5.39 |
|||
| Supports | First : | 4.77 | Second : | 3.85 |
| MAs | MA(5) : | 6.01 |
MA(20) : | 5.15 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 89.5 |
D(3) : | 89.3  |
| RSI | RSI(14): 64.3 |
|||
| 52-week | High : | 9.39 | Low : | 3.36 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ AEON ] has closed below upper band by 19.0%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 6.09 - 6.11 | 6.11 - 6.13 |
| Low: | 5.99 - 6.02 | 6.02 - 6.04 |
| Close: | 6.02 - 6.06 | 6.06 - 6.1 |
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.
Thu, 07 Dec 2023
Midday Stock Roundup: Rivian Gets Buy Rating From Stifel - Orange County Business Journal
Thu, 19 Oct 2023
AEON Biopharma, Inc. Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the ... - Marketscreener.com
Thu, 19 Oct 2023
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive ... - BioSpace
Wed, 30 Aug 2023
Thinking about buying stock in Mullen Automotive, Traction Uranium, Aeon Biopharma, BigBear.ai Holdings, or Lumen ... - Marketscreener.com
Mon, 07 Aug 2023
Evolus, Aeon Biopharma Tout Potential to Wall Street - Orange County Business Journal
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|